P123 | IBRUTINIB AND VENETOCLAX IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS OUTSIDE CLINICAL TRIALS: A SINGLE-CENTER REAL-WORLD EXPERIENCE

Introduction: The combination of ibrutinib, a Bruton's tyrosine kinase inhibitor, and venetoclax, a BCL-2 inhibitor, has shown synergistic efficacy in chronic lymphocytic leukemia (CLL). Pivotal trials like CAPTIVATE and GLOW report high rates of complete remission (CR) and undetectable minimal res...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	A. Tomasso, I. Innocenti *, L. Stirparo *, A. Fresa, A. Mosca, F. Iadevaia, T. Quaranta, F. Guglielmi, F. Autore, L. Laurenti
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	Ferrata Storti Foundation 2025-09-01
Σειρά:	Haematologica
Διαθέσιμο Online:	https://haematologica.org/article/view/12420
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!